因子H自身抗体与英国和爱尔兰儿童非典型溶血性尿毒症综合征相关
该回顾性队列分析了英国和爱尔兰175例非典型溶血性尿毒症综合征(aHUS)患儿,其中17例因子H自身抗体滴度高于国际标准。7例合并补体通路基因罕见变异;血浆置换组肾脏恢复率低,而未用免疫抑制者复发率高(5/7);依库珠单抗治疗者均获持续缓解。结论支持以依库珠单抗替代血浆置换治疗因子H自身抗体介导的aHUS。
要点
- 因子H自身抗体阳性aHUS患儿中约四成合并补体基因罕见变异。
- 血浆置换肾脏恢复率低,未用免疫抑制者复发率高(5/7)。
- 依库珠单抗治疗者均获持续缓解,支持其作为首选治疗。
核心结论
- 因子H自身抗体介导的儿童aHUS,当前实践主张以依库珠单抗起始治疗,而非血浆置换联合或不联合免疫抑制。
研究设计与样本
- 回顾性队列分析,纳入英国和爱尔兰175例表现为aHUS的儿童,检测因子H自身抗体,其中17例滴度高于国际标准。
主要发现
- 17例因子H自身抗体阳性患儿中,7例合并补体通路组分或调节因子基因的罕见变异。
- 2例仅接受支持治疗者均发展为终末期肾衰竭。
- 11例接受血浆置换者中7例肾脏恢复率不佳。
- 6例接受依库珠单抗治疗者均恢复肾功能。
- 血浆置换治疗者未采用免疫抑制预防复发,复发率高(5/7),但再治疗可恢复肾功能;依库珠单抗治疗者均获持续缓解。
关键数值与推荐
- 因子H自身抗体滴度高于国际标准者17例。
- 血浆置换组11例中7例肾脏恢复率不佳。
- 未免疫抑制者复发5/7。
- 依库珠单抗组6例均恢复肾功能并持续缓解。
- 5例接受肾移植,1例合并功能性显著CFI突变者复发。
临床怎么用
- 对因子H自身抗体介导的儿童aHUS,优先启动依库珠单抗治疗。
- 血浆置换联合或不联合免疫抑制并非首选,尤其需权衡免疫抑制相关并发症。
- 肾移植前需评估补体基因变异,尤其CFI突变者复发风险需关注。
局限性
- 回顾性分析,样本量小,结论强度有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Factor H autoantibodies can impair complement regulation, resulting in atypical hemolytic uremic syndrome, predominantly in childhood. There are no trials investigating treatment, and clinical practice is only informed by retrospective cohort analysis. Here we examined 175 children presenting with atypical hemolytic uremic syndrome in the United Kingdom and Ireland for factor H autoantibodies that included 17 children with titers above the international standard. Of the 17, seven had a concomitant rare genetic variant in a gene encoding a complement pathway component or regulator. Two children received supportive treatment; both developed established renal failure. Plasma exchange was associated with a poor rate of renal recovery in seven of 11 treated. Six patients treated with eculizumab recovered renal function. Contrary to global practice, immunosuppressive therapy to prevent relapse in plasma exchange-treated patients was not adopted due to concerns over treatment-associated complications. Without immunosuppression, the relapse rate was high (five of seven). However, reintroduction of treatment resulted in recovery of renal function. All patients treated with eculizumab achieved sustained remission. Five patients received renal transplants without specific factor H autoantibody-targeted treatment with recurrence in one who also had a functionally significant CFI mutation. Thus, our current practice is to initiate eculizumab therapy for treatment of factor H autoantibody-mediated atypical hemolytic uremic syndrome rather than plasma exchange with or without immunosuppression. Based on this retrospective analysis we see no suggestion of inferior treatment, albeit the strength of our conclusions is limited by the small sample size.
引用
- Brocklebank V, Johnson S, Sheerin TP, et al. Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland. Kidney Int. 2017. PMID: 28750931. doi:10.1016/j.kint.2017.04.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。